Using Angiotensin II to Improve Targeting of Cancer Treatment in Liver Metastases
Author Information
Author(s): J.A. Goldberg, J.A.K. Thomson, M.S. Bradnam, J. Fenner, R.G. Bessent, J.H. McKillop, D.J. Kerr, C.S. McArdle
Primary Institution: Royal Infirmary, Glasgow
Hypothesis
Can angiotensin II enhance the targeting of cytotoxic-loaded microspheres to colorectal liver metastases?
Conclusion
Angiotensin II significantly improves the targeting of microspheres to tumors in patients with colorectal liver metastases.
Supporting Evidence
- The median tumor:normal ratio improved from 3.4:1 to 7.3:1 after angiotensin II administration.
- The median improvement factor in tumor targeting was 1.8.
- Two patients had hypervascular tumors that complicated the assessment of angiotensin II's effectiveness.
Takeaway
This study found that a drug called angiotensin II can help deliver cancer treatment more directly to tumors in the liver, making it more effective.
Methodology
The study used scintigraphic imaging techniques to assess the targeting ability of angiotensin II in patients with colorectal liver metastases.
Limitations
The study's results may be affected by the proximity of normal liver tissue to tumors and the resolution of imaging techniques.
Participant Demographics
Patients with biopsy-confirmed advanced colorectal hepatic metastases.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website